View Older Stories View More Recent Stories
-
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
-
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
-
Moderna receives EU approval for first flu-COVID combination vaccine
-
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
-
Moderna to Present at Upcoming Conferences in May 2026
-
Moderna presents melanoma therapy data showing 83% response rate
-
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026
-
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
-
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
-
US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
-
Moderna shares jump as settlement removes major legal overhang
-
Moderna (MRNA) call put ratio 2.4 calls to 1 put into resolves litigation
-
Jefferies Reiterates Hold Rating on Moderna (MRNA): "cash breakeven guidance is clearer"
-
After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
-
Moderna settles patent dispute with Arbutus for $950 million
-
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
-
EMA committee recommends approval for Moderna's flu-COVID combo vaccine
-
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influen
-
Stifel: 'We can see why QURE shares are lower on CNBC comments from FDA'
-
Moderna (MRNA) PT Raised to $69 at Piper Sandler
-
BioNTech sues Moderna for U.S. patent infringement over covid vaccine MNEXspike - Court filing
-
Moderna to Present at Upcoming Conferences in March 2026
-
FDA accepts Moderna flu vaccine application for review
-
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
-
Moderna (MRNA) PT Raised to $45 at Bernstein SocGen Group
-
Moderna (MRNA) PT Raised to $30 at RBC Capital
-
Moderna (MRNA) Tops Q4 EPS by 51c, Beats on Revenue
-
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
-
Moderna earnings preview Q4: weak print expected amid vaccine slowdown
-
Moderna (MRNA) call put ratio 1.2 calls to 1 put into quarter results
-
Moderna (MRNA) call put ratio 1.9 calls to 1 put into quarter results
-
Moderna Stock Alert: - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Moderna Investors - MRNA
-
Moderna (MRNA) call put ratio 4.3 calls to 1 put into headlines and quarter results
-
Moderna (MRNA) PT Lowered to $24 at BofA Securities
-
Moderna receives FDA refusal to review flu vaccine application
-
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
-
Moderna signs five-year agreement with Mexico for vaccine supply
-
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
-
Arbutus Biopharma wins patent ruling against Moderna
-
Moderna names David Berman as chief development officer
-
Dr. David Berman to Join Moderna as Chief Development Officer
-
Moderna (MRNA) PT Lowered to $17 at Leerink Partners
-
Moderna partners with Recordati for rare disease drug commercialization
-
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
-
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
-
Moderna (MRNA) curbing investment in vaccine trials due to U.S. backlash - Bloomberg
-
This U.S. biotech stock is Bernstein's Top Pick for 2026
-
Moderna (MRNA) PT Raised to $35 at Bernstein SocGen Group
-
Investing.com’s stocks of the week
-
Moderna and Merck report sustained melanoma treatment benefits at 5 years
